IQVIA Rallies on Easing Biotech Funding Concerns After 31% One-Month Dip
In its Q4 2025 investor letter, Broyhill Asset Management cited IQVIA Holdings as a top contributor after reshaping a portfolio that fell 1.4% versus the MSCI ACWI’s 22.9% gain. IQVIA’s one-month return of -31.3% and 52-week decline of 13.2% contrast with its $27.6 billion market capitalization.
1. Broyhill’s Q4 Portfolio Review
Broyhill Asset Management’s fourth-quarter 2025 letter highlighted IQVIA Holdings as one of its three largest contributors after the firm reshaped its portfolio to trade at a notable discount. The portfolio underperformed with a 1.4% decline versus a 22.9% gain for the MSCI ACWI during the year, underscoring a contrarian strategy.
2. Easing Biotech Funding Concerns
IQVIA contributed meaningfully as fears around biotech funding and clinical activity began to subside, triggering the first leg of the industry rally. Broyhill expects the sector recovery to accelerate, positioning IQVIA’s clinical research services and infrastructure capabilities as key catalysts.
3. Stock Performance and Hedge Fund Interest
IQVIA’s shares closed at $161.91 on February 25, representing a 31.28% drop over one month and a 13.18% decline over 52 weeks. Hedge fund holdings increased to 69 portfolios from 61 last quarter, reflecting growing investor interest amid improving market fundamentals.